Executive Chairman of the Board of Directors
Mr. Stewart has served as Achieve’s Chairman and as a director since Achieve was founded in May 2015. Mr. Stewart is also a founder and a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson’s disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single purpose central nervous system company, during 2009, prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc.
Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single purpose central nervous system company, from 2013 to 2014 prior to Brabant Pharma’s acquisition by Zogenix Inc. He was a co-founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson’s disease and Huntington’s disease, from 2000 to 2007. Mr. Stewart was a co-founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such positions from 1995 to 1998. Mr. Stewart holds a Bachelor of Science degree in Business Administration from the University of Bath.
Chief Executive Officer
Mr. John Bencich is an experienced financial executive who has spent over 20 years guiding financial and corporate strategy in the life sciences and technology industries. Before his appointment to Chief Executive Officer in 2020, Mr. Bencich served as Achieve Life Sciences Chief Financial and Operating Officer. Prior to joining Achieve Life Sciences in 2017, John served as CFO of OncoGenex Pharmaceuticals, a publicly traded biotechnology company. Before joining OncoGenex in 2014, John served as CFO of Integrated Diagnostics and Allozyne, both private VC-backed companies. Earlier he served as the CFO and Treasurer of Trubion Pharmaceuticals, a publicly traded biotechnology company where he helped complete the successful sale of the company to Emergent BioSolutions. Prior to his role at Trubion, he led the global financial operations for Onyx Software Corporation, a publicly traded software company through its sale to Battery Ventures. John started his career at Ernst & Young LLP. He graduated from the University of San Diego with a BA in Accounting, earned his MBA from Seattle University and was a Certified Public Accountant in the state of Washington for 17 years.
Cindy Jacobs, Ph.D., M.D.
President and Chief Medical Officer
Dr Jacobs is an experienced executive in drug development with expertise in several indications and over 30 years’ experience in Biotechnology/Pharmaceutical industry. Dr Jacobs has achieved regulatory success in several product approvals. Dr. Jacobs currently serves on the Board of Directors of Achieve Life Sciences, Inc., Pacylex Pharmaceuticals Inc., and HiberCell Inc. Prior to joining Achieve Life Sciences as Executive Vice President and Chief Medical Officer in 2017, Dr. Jacobs served as OncoGenex’s Executive Vice President and Chief Medical Officer since August 2008, and had been Executive Vice President and Chief Medical Officer of OncoGenex Technologies Inc. from September 2005 to August 2008. From 1999 to July 2005, Dr. Jacobs served as Chief Medical Officer and Senior Vice President, Clinical Development of Corixa Corporation. Prior to 1999, Dr. Jacobs held Vice President, Clinical Research positions at two other biopharmaceutical companies. Dr. Jacobs received her Bachelor’s degree in Microbiology from Montana State University, her Master’s degree and Ph.D. degree in Veterinary Pathology/Microbiology from Washington State University and an M.D. degree from the University of Washington Medical School. She has in-depth biotechnology experience in preclinical development, pharmacokinetic/drug metabolism studies, toxicology studies, clinical operations, Phase 1-4 trials in a variety of therapeutic areas, regulatory affairs, biostatistics, data management, medical information and quality assurance. Based on her preclinical work at Immunex Corporation, she is one of 2 inventors on the patent for Enbrel.
Bridget Martell, M.A., M.D.
Dr. Martell is a high impact, results-oriented scientific biotech executive with breathe and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell is currently President and CEO of Artizan Biosciences, Inc. and an independent Director for Aligos Therapeutics. She has held leadership and C-suite executive roles at companies including Kura Oncology where she led the Menin Inhibitor Program and at Juniper Pharmaceuticals where she led the development program for a Bob Langer combined drug device technology that was out licensed for $131M. She started her pharma career at Pfizer where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and ultimately Biosimilars Medical Head. She began her clinical investigation career at Yale with a Career Development Award where she led a therapeutic cocaine vaccine trial and as Robert Wood Johnson Clinical Scholar. She was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.
Vaughn B. Himes, Ph.D.
Vaughn B. Himes, Ph.D. has served as Chief Technical Officer at Seagen, Inc. since August 2016. Dr. Himes joined Seagen as Executive Vice President, Technical Operations in April 2009 and served as Executive Vice President, Technical Operations and Process Science from July 2012 until August 2016. Previously, Dr. Himes was with ZymoGenetics, Inc. from November 2005 to March 2009, most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. From March 2003 to October 2005, he was Vice President, Manufacturing at Corixa, Inc. Prior to that, he held Vice President positions in manufacturing and development at Targeted Genetics and Genovo, Inc. Dr. Himes received a B.A. in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota.
Donald R. Joseph
Mr. Joseph currently serves as Chief Legal Officer and Board Secretary of Acer Therapeutics Inc., a publicly held biopharmaceutical company, and has served as an adviser and consultant to biopharmaceutical and global health organizations. He has over twenty years of biopharmaceutical industry experience, including senior management positions in global health non-profit organizations. Mr. Joseph served as the Chief Legal Officer and Board Secretary of Humanigen, formerly known as KaloBios Pharmaceuticals, Inc., a publicly listed company, from June 2013 to November 2015. Prior to KaloBios, he was Chief Executive Officer of BIO Ventures for Global Health, or BVGH, from February to November 2012 and Chief Operating Officer from April 2010 to January 2012. He is a former Chairman and Secretary and director of BVGH. He previously served as general counsel, corporate secretary, and in other senior management roles at publicly held biopharmaceutical companies, including Abgenix and Renovis. Before entering the life sciences industry, Mr. Joseph practiced business law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world’s largest law firms. He received his J.D. degree from the University of Texas School of Law, with honors.
Jay M. Moyes
Mr. Moyes currently serves as Chief Financial Officer of Sera Prognostics, Inc., a public commercial stage biotechnology company focused on improving maternal and neonatal health through innovative biomarker approaches, and currently serves on the board of directors of BioCardia, Inc., and Puma Biotechnology, Inc. He previously served on the boards of Predictive Technology Group, Osiris Therapeutics, Inc., Integrated Diagnostics and as Chief Financial Officer and Director of Amedica Corporation (now SINTX Technologies). Mr. Moyes also served as Chief Financial Officer of CareDx, a publicly traded cardiovascular diagnostics company. Prior to that, he served as Chief Financial Officer of Myriad Genetics, Inc., a publicly held molecular diagnostics company. Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc. from 1991 until 1993, a privately held animal genetics company. Mr. Moyes held various positions with the accounting firm of KPMG from 1979 to 1991. He also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 to 2006. Mr. Moyes holds a Masters of Business Administration from the University of Utah, a Bachelor of Arts in economics from Weber State University, and was formerly a Certified Public Accountant.
Martin Mattingly, Pharm.D.
Dr. Mattingly served as a director of Achieve since June 2010. Since December 2014 he has served as a director of TRACON Pharmaceuticals, Inc. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007, Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005, Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Pharm.D. degree from the University of Kentucky.